Pyrrolopyrimidine compounds used as TLR7 agonist
The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection.
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof
wherein
L 1 is —O—;
L 2 is —CH 2 —;
R 1 is selected from the group consisting of hydrogen and C 1-10 alkyl, wherein the above C 1-10 alkyl is optionally substituted by one or more R 4 ;
R 2 is selected from the group consisting of hydrogen, cyano, COOH, and CONH 2 ;
B is selected from the group consisting of aryl and heteroaryl;
L 3 is selected from the group consisting of C 0-6 alkylene and imino, wherein the above C 0-6 alkylene and imino are optionally substituted by one or more R 4 ;
R 3 is selected from the group consisting of hydrogen, amino, C 1-10 alkyl, C 3-10 cyclohydrocarbyl, and 3-10 membered heterocyclohydrocarbyl, wherein the above amino, C 1-10 alkyl, C 3-10 cyclohydrocarbyl, and 3-10 membered heterocyclohydrocarbyl are optionally substituted by one or more R 4 ; or
R 3 and L 3 together with the adjacent atom at the ring B form a saturated or unsaturated 5-8 membered ring, the 5-8 membered ring is optionally substituted by one or more R 4 ;
n is 0, 1, 2, 3, 4 or 5;
R 4 is selected from the group consisting of halogen, —R, —OR, and ═O; and
R is independently selected from the group consisting of H and C 1-8 alkyl.
2. The compound according to claim 1 , characterized in that, R 1 is selected from the group consisting of hydrogen and C 1-6 alkyl, wherein the above C 1-6 alkyl is optionally substituted by one or more R 4 .
3. The compound according to claim 2 , characterized in that, R 1 is selected from the group consisting of C 1-6 alkyl, wherein the above C 1-6 alkyl is optionally substituted by one or more R 4 .
4. The compound according to claim 1 , characterized in that, R 2 is selected from the group consisting of hydrogen, cyano and —CONH 2 .
5. The compound according to claim 1 , characterized in that, B is selected from the group consisting of phenyl and pyridyl.
6. The compound according to claim 1 , characterized in that, L 3 is selected from the group consisting of C 0-6 alkylene, wherein the above C 0-6 alkylene is optionally substituted by one or more R 4 .
7. The compound according to claim 1 , characterized in that, R 3 is selected from the group consisting of hydrogen, amino, C 1-6 alkyl and 3-8 membered heterocyclohydrocarbyl, wherein the above amino, C 1-6 alkyl and 3-8 membered heterocyclohydrocarbyl are optionally substituted by one or more R 4 ; or R 3 and L 3 together with the adjacent atom at the ring B form a saturated or unsaturated 5-8 membered ring, the 5-8 membered ring is optionally substituted by one or more R 4 .
8. The compound according to claim 1 . selected from:
or the pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition, comprising the compound according to claim 1 or the pharmaceutically acceptable salt thereof in a therapeutically effective amount and one or more pharmaceutically acceptable carriers or excipients.
10. A method for treating viral infection, comprising administering the compound according to claim 1 or the pharmaceutically acceptable salt thereof to a subject in need thereof.